Phase 3 Myelofibrosis Clinical Trials
6 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–6 of 6 trials
Recruiting
Phase 3
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
MyelofibrosisPolycythemia VeraPrimary Myelofibrosis+3 more
Merck Sharp & Dohme LLC400 enrolled21 locationsNCT06351631
Recruiting
Phase 3
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
Polycythemia VeraEssential ThrombocythemiaPrefibrotic/Early Primary Myelofibrosis+1 more
University Hospital, Brest1,308 enrolled42 locationsNCT05198960
Recruiting
Phase 3
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Swedish Orphan Biovitrum399 enrolled207 locationsNCT03165734
Recruiting
Phase 3
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
MyelofibrosisPrimary MyelofibrosisMF+2 more
Kartos Therapeutics, Inc.600 enrolled215 locationsNCT06479135
Recruiting
Phase 3
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
Myeloproliferative NeoplasmPrimary Myelofibrosis
PharmaEssentia150 enrolled1 locationNCT06468033
Recruiting
Phase 3
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia (PAC326)
Primary Myelofibrosis
Cell Therapeutics Inc.300 enrolled6 locationsACTRN12614000740695